Molecular Imaging to Predict Response to Targeted Therapies in Renal Cell Carcinoma
| Autor: | Philippe Robert, Nathalie Lassau, Ludovic de Rochefort, Ingrid Leguerney, Paule Opolon, Alexandre Ingels, Stéphanie Pitre-Champagnat, Sandra Robin, Marie Poirier-Quinot, Rose-Marie Dubuisson, Xavier Violas |
|---|---|
| Přispěvatelé: | Imagerie par Résonance Magnétique Médicale et Multi-Modalités (IR4M), Centre National de la Recherche Scientifique (CNRS)-Hôpital Bicêtre-Université Paris-Sud - Paris 11 (UP11), Unite de recherche en résonance magnétique médicale (U2R2M), Université Paris-Sud - Paris 11 (UP11)-Hôpital Bicêtre-Centre National de la Recherche Scientifique (CNRS), Guerbet Research, Guerbet, Institut Gustave Roussy (IGR), Vectorologie et transfert de gènes (VTG / UMR8121), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS), Spatio-Temporal Activity Recognition Systems (STARS), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria), Laboratoire Guerbet / Guerbet Research |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
Pathology medicine.medical_specialty Indoles lcsh:Medical technology Bevacizumab Article Subject medicine.medical_treatment [SDV]Life Sciences [q-bio] Antineoplastic Agents 030218 nuclear medicine & medical imaging Mice 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma Cell Line Tumor Immunochemistry Sunitinib Carcinoma Animals Humans Medicine Pyrroles Radiology Nuclear Medicine and imaging Everolimus Molecular Targeted Therapy Carcinoma Renal Cell Saline ComputingMilieux_MISCELLANEOUS medicine.diagnostic_test business.industry Magnetic resonance imaging medicine.disease Magnetic Resonance Imaging Molecular Imaging 3. Good health Treatment Outcome lcsh:R855-855.5 030220 oncology & carcinogenesis Heterografts business Research Article medicine.drug |
| Zdroj: | Contrast Media and Molecular Imaging Contrast Media and Molecular Imaging, Wiley, 2017, 2017, pp.1-8. ⟨10.1155/2017/7498538⟩ Contrast Media & Molecular Imaging, Vol 2017 (2017) Contrast Media and Molecular Imaging, 2017, 2017, pp.1-8. ⟨10.1155/2017/7498538⟩ Contrast Media & Molecular Imaging |
| ISSN: | 1555-4309 1555-4317 |
| DOI: | 10.1155/2017/7498538 |
| Popis: | Molecular magnetic resonance imaging targeted to an endothelial integrin involved in neoangiogenesis was compared to DCE-US and immunochemistry to assess the early response of three different therapeutic agents in renal cell carcinoma. Human A498 renal cells carcinoma was subcutaneously inoculated into 24 nude mice. Mice received either phosphate-buffered saline solution, sunitinib, everolimus, or bevacizumab during 4 days. DCE-US and molecular MRI targetingαvβ3 were performed at baseline and 4 days after treatment initiation. PI, AUC, relaxation rate variationsΔR2⁎, and percentage of vessels area quantified on CD31-stained microvessels were compared. Significant decreases were observed for PI and AUC parameters measured by DCE-US for bevacizumab group as early as 4 days, whereas molecularαvβ3-targeted MRI was able to detect significant changes in both bevacizumab and everolimus groups. Percentage of CD31-stained microvessels was significantly correlated with DCE-US parameters, PI (R=0.87,p=0.0003) and AUC (R=0.81,p=0.0013). The percentage of vessel tissue area was significantly reduced (p<0.01) in both sunitinib and bevacizumab groups. We report an early detection of neoangiogenesis modification after induction of targeted therapies, using DCE-US orαvβ3-targeted MRI. We consider these outcomes should encourage clinical trial developments to further evaluate the potential of this molecular MRI technique. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text